These studies indicate that the FAK+MEK inhibitor combination may be repurposable for other tumors; however, improving the physicochemical properties of each individual compound component, such as CNS penetrance, may be required to achieve optimal activity in GBM. This evidence concerns the gene PTK2 and glioblastoma.